Join us   Log in  

NJBMS - Volume 1, Issue 2., October - December 2010

Pages: 83-90
Print Article   Download XML  Download PDF


Author: Dr. Glory Josephine, Dr. Vijaybabu .K, Dr. Punnagai .K, Dr. Arul Amutha .E, Dr. Kavitha Inbaraj .S.D

Category: Pharmacology


Aim: To measure the effect of Acamprosate/Disulfiram on serum lipid profile and lactate dehydrogenate. Methods: Participants were identified by screening through Alcohol Use Disorder Identification Test (AUDIT) with 8 or more than 8 score. Total 89 patients of 20-60 years withDSMIV criteriawere enrolled with history of alcohol consumption without de-addiction treatment. They were admitted and detoxified for 3 weeks. Enrolled participants were randomized among three groups consisting placebo, acamprosate and disulfiram. At baseline, serum lipid profile and LDH were measured and same were measured at the end of 4th and 8th week of treatment. Biochemical values were expressed as mean } SD and intergroup and time changes were expressed using "t test". One way Analysis of Variance F-Test was used to compare biochemical values among three groups. Results: Serum LDH value was found to be decreased compared to baseline in all treatment groups without intergroup variation. LDL, Triglyceride and total cholesterol were decreased in groups treated by acamprosate or placebo with statistical significance (P <0.01). It was continued to decrease till 8th week of treatment while they were significantly increased in disulfiram treated group. Triglyceride and total cholesterol were significantly increased in disulfiram group at 8th week of treatment than 4th week, moderately affecting lipid metabolism. Conclusion: Disulfiramis found detrimental to cardiovascular system by inducing atherosclerosis through hyper-lipidemia; physicians should be precautious in prescribing disulfiramin chronic alcoholics.